Opinion|Videos|November 18, 2024
Exploring Emerging Therapies in Vitiligo
Author(s)Seemal Desai, MD, FAAD
The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the most promising new vitiligo treatments?
- How has this knowledge shaped current treatment approaches and new therapies?
- How do vitiligo progression patterns affect treatment decisions and long-term management?
- Describe your process to assess and manage treatment-resistant disease.
- What is the role of newer targeted therapies in such cases?
Advertisement
Related to this article
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
2
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
5